EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Archived HIV-1 Drug Resistance Mutations: Role of Proviral HIV-1 DNA Genotype for the Management of Virological Responder People Living with HIV

Roberta Campagna iD, Chiara Nonne iD, Guido Antonelli iD, Ombretta Turriziani iD

Viruses · 2024

DOI: 10.3390/v16111697 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Viruses, 2024. Verfasst von Roberta Campagna und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy. Hauptthemen laut MEDLINE: HIV-1, HIV Infections, Drug Resistance, Viral, Proviruses. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 137 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite its effectiveness in controlling plasma viremia, antiretroviral therapy (ART) cannot target proviral DNA, which remains an obstacle to HIV-1 eradication. When treatment is interrupted, the reservoirs can act as a source of viral rebound, highlighting the value of proviral DNA as an additional source of information on an individual’s overall resistance burden. In cases where the viral load is too low for successful HIV-1 RNA genotyping, HIV-1 DNA can help identify resistance mutations in treated individuals. The absence of treatment history, the need to adjust ART despite undetectable viremia, or the presence of LLV further support the use of genotypic resistance tests (GRTs) on HIV-1 DNA. Conventionally, GRTs have been achieved through Sanger sequencing, but the advances in NGS are leading to an increase in its use, allowing the detection of minority variants present in less than 20% of the viral population. The clinical significance of these mutations remains under debate, with interpretations varying based on context. Additionally, proviral DNA is subject to APOBEC3-induced hypermutation, which can lead to defective, nonviable viral genomes, a factor that must be considered when performing GRTs on HIV-1 DNA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV-1HIV InfectionsDrug Resistance, ViralProvirusesMutationGenotypeDNA, ViralViral LoadAnti-HIV AgentsHumans

Stichwörter der Autor:innen

APOBECDNA GRTHIV-1NGSSanger sequencingreservoir

Substanzen

DNA, ViralAnti-HIV Agents

Autor:innen und Institutionen

  • Department of Molecular Medicine, Sapienza University of Rome, 00185 Rome, Italy.

ORCID-Profile: Roberta Campagna, Chiara Nonne, Guido Antonelli, Ombretta Turriziani

Zitieren

APA

Campagna, R., Nonne, C., Antonelli, G., & Turriziani, O. (2024). Archived HIV-1 Drug Resistance Mutations: Role of Proviral HIV-1 DNA Genotype for the Management of Virological Responder People Living with HIV. Viruses. https://doi.org/10.3390/v16111697

Vancouver

Campagna R, Nonne C, Antonelli G, Turriziani O. Archived HIV-1 Drug Resistance Mutations: Role of Proviral HIV-1 DNA Genotype for the Management of Virological Responder People Living with HIV. Viruses. 2024. doi:10.3390/v16111697

BibTeX
@article{Campagna2024,
  author = {Campagna, Roberta and Nonne, Chiara and Antonelli, Guido and Turriziani, Ombretta},
  title = {Archived HIV-1 Drug Resistance Mutations: Role of Proviral HIV-1 DNA Genotype for the Management of Virological Responder People Living with HIV},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16111697}
}
Kostenlos starten →